Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Dosimetric predictors of toxicity and quality of life following prostate stereotactic ablative radiotherapy.

Alayed Y, Davidson M, Quon H, Cheung P, Chu W, Chung HT, Vesprini D, Ong A, Chowdhury A, Liu SK, Panjwani D, Helou J, Musunuru HB, Pang G, Korol R, Ravi A, McCurdy B, Zhang L, Mamedov A, Deabreu A, Commisso A, Commisso K, D'Alimonte L, Ho L, Bhounr Z, Loblaw A.

Radiother Oncol. 2019 Dec 3;144:135-140. doi: 10.1016/j.radonc.2019.11.017. [Epub ahead of print]

PMID:
31809979
2.

The use of mirabegron in neurogenic bladder: a systematic review.

El Helou E, Labaki C, Chebel R, El Helou J, Abi Tayeh G, Jalkh G, Nemr E.

World J Urol. 2019 Dec 5. doi: 10.1007/s00345-019-03040-x. [Epub ahead of print] Review.

PMID:
31802206
3.

A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy.

Liu W, Zukotynski K, Emmett L, Chung HT, Chung P, Wolfson R, Rachinsky I, Kapoor A, Metser U, Loblaw A, Morton G, Sexton T, Lock M, Helou J, Berlin A, Boylan C, Archer S, Pond G, Bauman G.

Int J Radiat Oncol Biol Phys. 2019 Nov 12. pii: S0360-3016(19)33971-9. doi: 10.1016/j.ijrobp.2019.11.001. [Epub ahead of print]

PMID:
31730876
4.

MRI assisted focal boost integrated with HDR monotherapy study in low and intermediate risk prostate cancer (MARS): Results from a phase II clinical trial.

Alayed Y, D'Alimonte L, Helou J, Ravi A, Morton G, Chung HT, Haider M, McGuffin M, Zhang L, Loblaw A.

Radiother Oncol. 2019 Dec;141:144-148. doi: 10.1016/j.radonc.2019.09.011. Epub 2019 Sep 26.

PMID:
31564554
5.

Triggers, clinical manifestations, and management of pediatric erythema multiforme: A systematic review.

Zoghaib S, Kechichian E, Souaid K, Soutou B, Helou J, Tomb R.

J Am Acad Dermatol. 2019 Sep;81(3):813-822. doi: 10.1016/j.jaad.2019.02.057. Epub 2019 Jul 19. Review.

PMID:
31331726
6.

Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trials.

Alayed Y, Quon H, Cheung P, Chu W, Chung HT, Vesprini D, Ong A, Chowdhury A, Panjwani D, Helou J, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Zhang L, Mamedov A, Deabreu A, Commisso A, Commisso K, Loblaw A.

Radiother Oncol. 2019 Nov;140:105-109. doi: 10.1016/j.radonc.2019.06.018. Epub 2019 Jun 29.

PMID:
31265940
7.

Prostate-specific Antigen Bounce After Stereotactic Body Radiotherapy for Prostate Cancer: A Pooled Analysis of Four Prospective Trials.

Roy S, Loblaw A, Cheung P, Chu W, Chung HT, Vesprini D, Ong A, Chowdhury A, Panjwani D, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Helou J, Zhang L, Mamedov A, Deabreu A, Quon HC.

Clin Oncol (R Coll Radiol). 2019 Sep;31(9):621-629. doi: 10.1016/j.clon.2019.05.001. Epub 2019 May 21.

PMID:
31126725
8.

Longitudinal Extensive Transverse Myelitis in an Immunocompetent Older Individual-A Rare Complication of Varicella-Zoster Virus Reactivation.

Abbas SA, El Helou J, Chalah MA, Hilal H, Saliba G, Abboud H, Ayache SS.

Medicina (Kaunas). 2019 May 23;55(5). pii: E201. doi: 10.3390/medicina55050201.

9.

Predictive factors for persistent and late radiation complications in breast cancer survivors.

Fekrmandi F, Panzarella T, Dinniwell RE, Helou J, Levin W.

Clin Transl Oncol. 2019 May 23. doi: 10.1007/s12094-019-02133-8. [Epub ahead of print]

PMID:
31123988
10.

Dose to the bladder neck in MRI-guided high-dose-rate prostate brachytherapy: Impact on acute urinary toxicity and health-related quality of life.

Sanmamed N, Chung P, Berlin A, Adleman J, Borg J, Lao B, Ghai S, Weersink R, Simeonov A, Rink A, Menard C, Helou J.

Brachytherapy. 2019 Jul - Aug;18(4):477-483. doi: 10.1016/j.brachy.2019.02.003. Epub 2019 May 17.

PMID:
31109872
11.

Two StereoTactic ablative radiotherapy treatments for localized prostate cancer (2STAR): Results from a prospective clinical trial.

Alayed Y, Cheung P, Chu W, Chung H, Davidson M, Ravi A, Helou J, Zhang L, Mamedov A, Commisso A, Commisso K, Loblaw A.

Radiother Oncol. 2019 Jun;135:86-90. doi: 10.1016/j.radonc.2019.03.002. Epub 2019 Mar 19.

PMID:
31015175
12.

Optimized penile surface mold brachytherapy using latest stereolithography techniques: A single-institution experience.

D'Alimonte L, Ravi A, Helou J, Morrison D, Mendez LC, Easton H, Morton G.

Brachytherapy. 2019 May - Jun;18(3):348-352. doi: 10.1016/j.brachy.2019.01.002. Epub 2019 Feb 2.

PMID:
30718175
13.

NMDA receptor antibody in teratoma-related opsoclonus-myoclonus syndrome.

Urriola NX, Helou J, Maamary J, Pogson J, Lee F, Parratt K, Gillis D, Fulham MJ, Halmágyi GM.

J Clin Neurosci. 2018 Dec;58:203-204. doi: 10.1016/j.jocn.2018.10.011. Epub 2018 Oct 16.

PMID:
30340968
14.

Quality of life changes after stereotactic ablative radiotherapy for liver metastases: A prospective cohort analysis.

Helou J, Thibault I, Chu W, Munoz-Schuffenegger P, Erler D, Rodrigues G, Warner A, Chan KKW, Chow E, Korol R, Davidson M, Chung HT.

Radiother Oncol. 2018 Dec;129(3):435-440. doi: 10.1016/j.radonc.2018.09.011. Epub 2018 Sep 28.

PMID:
30274721
15.

Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?

Merino Lara T, Helou J, Poon I, Sahgal A, Chung HT, Chu W, Soliman H, Ung Y, Verma S, Cheema P, Cheng S, Khanna S, Erler D, Zhang L, Cheung P.

Lung Cancer. 2018 Oct;124:219-226. doi: 10.1016/j.lungcan.2018.08.005. Epub 2018 Aug 7.

PMID:
30268464
16.

Retinal thickness measurements in sickle cell patients with HbSS and HbSC genotype.

Lim WS, Magan T, Mahroo OA, Hysi PG, Helou J, Mohamed MD.

Can J Ophthalmol. 2018 Aug;53(4):420-424. doi: 10.1016/j.jcjo.2017.10.006. Epub 2017 Dec 11.

17.

[Definitions of oligometastatic disease and new treatment concepts].

Kissel M, Helou J, Thariat J.

Bull Cancer. 2018 Jul - Aug;105(7-8):696-706. doi: 10.1016/j.bulcan.2018.04.012. Epub 2018 Jun 20. Review. French.

PMID:
29935914
18.

Nivolumab in the Treatment of Metastatic Renal Cell Carcinoma: A Cost-Utility Analysis.

Raphael J, Sun Z, Bjarnason GA, Helou J, Sander B, Naimark DM.

Am J Clin Oncol. 2018 Dec;41(12):1235-1242. doi: 10.1097/COC.0000000000000451.

PMID:
29727313
19.

Dose escalation for prostate stereotactic ablative radiotherapy (SABR): Late outcomes from two prospective clinical trials.

Alayed Y, Cheung P, Pang G, Mamedov A, D'Alimonte L, Deabreu A, Commisso K, Commisso A, Zhang L, Quon HC, Musunuru HB, Helou J, Loblaw DA.

Radiother Oncol. 2018 May;127(2):213-218. doi: 10.1016/j.radonc.2018.03.005. Epub 2018 Mar 24.

PMID:
29588072
20.

Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab.

Nasr F, El Rassy E, Maalouf G, Azar C, Haddad F, Helou J, Robert C.

Eur J Cancer. 2018 Mar;91:171-173. doi: 10.1016/j.ejca.2017.11.026. Epub 2017 Dec 26. No abstract available.

PMID:
29287903
21.

Use of hydrogel spacer for improved rectal dose-sparing in patients undergoing radical radiotherapy for localized prostate cancer: First Canadian experience.

Berlin A, Di Tomasso A, Ballantyne H, Patterson S, Lam T, Sundaramurthy A, Helou J, Bayley A, Chung P.

Can Urol Assoc J. 2017 Dec;11(12):373-375. doi: 10.5489/cuaj.4681. Epub 2017 Nov 1.

22.

Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis.

Raphael J, Helou J, Pritchard KI, Naimark DM.

Eur J Cancer. 2017 Nov;85:146-154. doi: 10.1016/j.ejca.2017.08.018. Epub 2017 Sep 18.

PMID:
28930692
23.

Stereotactic Body Radiotherapy versus Low Dose Rate Brachytherapy for Localised Prostate Cancer: a Cost-Utility Analysis.

Helou J, Torres S, Musunuru HB, Raphael J, Cheung P, Vesprini D, Chung HT, D'Alimonte L, Krahn M, Morton G, Loblaw A.

Clin Oncol (R Coll Radiol). 2017 Nov;29(11):718-731. doi: 10.1016/j.clon.2017.08.002. Epub 2017 Sep 12.

PMID:
28916284
24.

Dosimetric impact of intrafraction changes in MR-guided high-dose-rate (HDR) brachytherapy for prostate cancer.

Rink A, Borg J, Simeonov A, O'Leary G, Helou J, Ménard C, Chung P, Jaffray DA, Berlin A.

Brachytherapy. 2018 Jan - Feb;17(1):59-67. doi: 10.1016/j.brachy.2017.06.001. Epub 2017 Jul 29.

PMID:
28764881
25.

Spectrum of Autoimmune Bullous Diseases in the Middle East: A 15-Year Review.

Haber R, Helou J, Habr C, Tomb R.

Skinmed. 2017 Jun 1;15(3):181-186. eCollection 2017.

PMID:
28705277
26.

Stereotactic Ablative Radiation Therapy for Pulmonary Metastases: Histology, Dose, and Indication Matter.

Helou J, Thibault I, Poon I, Chiang A, Jain S, Soliman H, Erler D, Yeung L, Cheung P.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):419-427. doi: 10.1016/j.ijrobp.2017.02.093. Epub 2017 Feb 28.

PMID:
28463162
27.

Stereotactic ablative radiotherapy in the treatment of low and intermediate risk prostate cancer: Is there an optimal dose?

Helou J, D'Alimonte L, Quon H, Deabreu A, Commisso K, Cheung P, Chu W, Mamedov A, Davidson M, Ravi A, Loblaw A.

Radiother Oncol. 2017 Jun;123(3):478-482. doi: 10.1016/j.radonc.2017.03.006. Epub 2017 Apr 19.

PMID:
28433413
28.

Quantifying Health Utilities in Patients Undergoing Stereotactic Body Radiation Treatment for Liver Metastases for Use in Future Economic Evaluations.

Warren B, Munoz-Schuffenegger P, Chan KKW, Chu W, Helou J, Erler D, Chung H.

Clin Oncol (R Coll Radiol). 2017 Sep;29(9):e141-e147. doi: 10.1016/j.clon.2017.03.011. Epub 2017 Apr 12.

PMID:
28410779
29.

Evaluation of a Machine-Learning Algorithm for Treatment Planning in Prostate Low-Dose-Rate Brachytherapy.

Nicolae A, Morton G, Chung H, Loblaw A, Jain S, Mitchell D, Lu L, Helou J, Al-Hanaqta M, Heath E, Ravi A.

Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):822-829. doi: 10.1016/j.ijrobp.2016.11.036. Epub 2016 Nov 27.

PMID:
28244419
30.

Less Pain, More Gain: Lip Augmentation With Insulin Syringes.

Kechichian E, El Khoury R, Helou J.

Dermatol Surg. 2017 Jul;43(7):979-981. doi: 10.1097/DSS.0000000000001029. No abstract available.

PMID:
28221184
31.

Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy.

Morton G, Chung HT, McGuffin M, Helou J, D'Alimonte L, Ravi A, Cheung P, Szumacher E, Liu S, Al-Hanaqta M, Zhang L, Mamedov A, Loblaw A.

Radiother Oncol. 2017 Jan;122(1):87-92. doi: 10.1016/j.radonc.2016.10.019. Epub 2016 Nov 4.

PMID:
27823821
32.

Predictive Parameters of Symptomatic Hematochezia Following 5-Fraction Gantry-Based SABR in Prostate Cancer.

Musunuru HB, Davidson M, Cheung P, Vesprini D, Liu S, Chung H, Chu W, Mamedov A, Ravi A, D'Alimonte L, Commisso K, Helou J, Deabreu A, Zhang L, Loblaw A.

Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1043-51. doi: 10.1016/j.ijrobp.2015.12.010. Epub 2015 Dec 23.

PMID:
27026311
33.

Evaluation of Nd:YAG laser device efficacy on onychomycosis: a case series of 30 patients.

Helou J, Maatouk I, Hajjar MA, Moutran R.

Mycoses. 2016 Jan;59(1):7-11. doi: 10.1111/myc.12425. Epub 2015 Nov 5.

PMID:
26537779
34.

Fractional CO2 laser treatment for a skin graft.

Stephan FE, Habre MB, Helou JF, Tohme RG, Tomb RR.

J Cosmet Laser Ther. 2016;18(1):46-7. doi: 10.3109/14764172.2015.1052508. Epub 2016 Jan 20.

PMID:
26052811
35.

Clinical evaluation of an endorectal immobilization system for use in prostate hypofractionated Stereotactic Ablative Body Radiotherapy (SABR).

Nicolae A, Davidson M, Easton H, Helou J, Musunuru H, Loblaw A, Ravi A.

Radiat Oncol. 2015 May 30;10:122. doi: 10.1186/s13014-015-0426-4.

36.

Laser treatment of onychomycosis: beware of ring block anesthesia!

Helou J, Korkomaz J, Haber R, Habre M, Tomb R.

Lasers Med Sci. 2015 Dec;30(9):2399-400. doi: 10.1007/s10103-015-1744-3. Epub 2015 Mar 27. No abstract available.

PMID:
25813157
37.

A case of generalized bromhidrosis following whole-body depilatory laser.

Helou J, Haber R, Kechichian E, Tomb R.

J Cosmet Laser Ther. 2015;17(6):318-20. doi: 10.3109/14764172.2015.1027232. Epub 2015 Apr 6.

PMID:
25803676
38.

High dose-rate brachytherapy boost for intermediate risk prostate cancer: Long-term outcomes of two different treatment schedules and early biochemical predictors of success.

Helou J, D'Alimonte L, Loblaw A, Chung H, Cheung P, Szumacher E, Danjoux C, Ravi A, Deabreu A, Zhang L, Morton G.

Radiother Oncol. 2015 Apr;115(1):84-9. doi: 10.1016/j.radonc.2015.02.023. Epub 2015 Mar 11.

PMID:
25770875
39.

4DCT Simulation With Synchronized Contrast Injection in Liver SBRT Patients.

Helou J, Karotki A, Milot L, Chu W, Erler D, Chung HT.

Technol Cancer Res Treat. 2016 Feb;15(1):55-9. doi: 10.1177/1533034615572341. Epub 2015 Mar 2.

PMID:
25731803
40.

A comparative study of quality of life in patients with localized prostate cancer treated at a single institution: stereotactic ablative radiotherapy or external beam+high dose rate brachytherapy boost.

Helou J, Morton G, Zhang L, Deabreu A, D'Alimonte L, Elias E, Musunuru HB, Mamedov A, Ravi A, Chung H, Cheung P, Loblaw A.

Radiother Oncol. 2014 Dec;113(3):404-9. doi: 10.1016/j.radonc.2014.10.013. Epub 2014 Nov 14.

PMID:
25466371
41.

The clinical significance of persistent cancer cells on prostate biopsy after high-dose-rate brachytherapy boost for intermediate-risk prostate cancer.

D'Alimonte L, Helou J, Sherman C, Loblaw A, Chung HT, Ravi A, Deabreu A, Zhang L, Morton G.

Brachytherapy. 2015 May-Jun;14(3):309-14. doi: 10.1016/j.brachy.2014.10.003. Epub 2014 Nov 25.

PMID:
25466361
42.

Measurement of mean cardiac dose for various breast irradiation techniques and corresponding risk of major cardiovascular event.

Merino Lara TR, Fleury E, Mashouf S, Helou J, McCann C, Ruschin M, Kim A, Makhani N, Ravi A, Pignol JP.

Front Oncol. 2014 Oct 22;4:284. doi: 10.3389/fonc.2014.00284. eCollection 2014.

43.

Images in vascular medicine. Nicolau livedoid dermatitis occurring after sclerotherapy.

Korkomaz J, Maatouk I, Moutran R, Hélou J.

Vasc Med. 2014 Oct;19(5):415-6. doi: 10.1177/1358863X14537884. No abstract available.

PMID:
25305275
44.

A "sexually transmitted" fixed drug reaction.

Maatouk I, Moutran R, Fahed M, Helou J.

Sex Transm Dis. 2014 Oct;41(10):626-7. doi: 10.1097/OLQ.0000000000000173. No abstract available.

PMID:
25211260
45.

Reporting a case of peri-orificial herpes of the face due to HSV-1 recurrence: a new form?

Hélou J, Maatouk I, Haddad F.

J Clin Virol. 2014 Nov;61(3):470-1. doi: 10.1016/j.jcv.2014.08.003. Epub 2014 Aug 13. No abstract available.

PMID:
25176523
46.

Dosimetric and patient correlates of quality of life after prostate stereotactic ablative radiotherapy.

Elias E, Helou J, Zhang L, Cheung P, Deabreu A, D'Alimonte L, Sethukavalan P, Mamedov A, Cardoso M, Loblaw A.

Radiother Oncol. 2014 Jul;112(1):83-8. doi: 10.1016/j.radonc.2014.06.009. Epub 2014 Jul 5.

PMID:
25005578
47.

Fractional laser for vitiligo treated by 10,600 nm ablative fractional carbon dioxide laser followed by sun exposure.

Hélou J, Maatouk I, Obeid G, Moutran R, Stéphan F, Tomb R.

Lasers Surg Med. 2014 Aug;46(6):443-8. doi: 10.1002/lsm.22260. Epub 2014 May 30.

PMID:
24889492
48.

Diabetic neuropathy and Nd-YAG (1064 nm) laser for onychomycosis: be careful.

Moutran R, Maatouk I, Hélou J.

J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1239-40. doi: 10.1111/jdv.12466. Epub 2014 Mar 24. No abstract available.

PMID:
24661384
49.

The genome-wide landscape of DNA methylation and hydroxymethylation in response to sleep deprivation impacts on synaptic plasticity genes.

Massart R, Freyburger M, Suderman M, Paquet J, El Helou J, Belanger-Nelson E, Rachalski A, Koumar OC, Carrier J, Szyf M, Mongrain V.

Transl Psychiatry. 2014 Jan 21;4:e347. doi: 10.1038/tp.2013.120.

50.

[Helical tomotherapy in the treatment of malignant pleural mesothelioma: The impact of low doses on pulmonary and oesophageal toxicity].

Helou J, Clément-Colmou K, Sylvestre A, Campion L, Amessis M, Zefkili S, Raphael J, Bonnette P, Le Pimpec Barthes F, Périgaud C, Mahé MA, Giraud P.

Cancer Radiother. 2013 Dec;17(8):755-62. doi: 10.1016/j.canrad.2013.06.045. Epub 2013 Nov 20. French.

PMID:
24269017

Supplemental Content

Support Center